NHF hosts 17th workshop on gene therapy header

NHF hosts 17th workshop on gene therapy

The National Hemophilia Foundation (NHF) recently hosted its 17th workshop on gene therapy, “AAV Gene Therapy & Novel Technologies Workshop: Understanding Neutralizing Antibodies and Genomic Analysis.”

Also available in: Français Español

The workshop—co-chaired by Glenn Pierce, MD, PhD, Vice President, Medical, WFH, and David Lillicrap, MD—has been held every few years since 1966. The high-level scientific meeting brings together experts from various fields, including immunologists, clinicians, researchers, regulators, and patients to discuss the latest advancements and challenges in the field of gene therapy for hemophilia.

During the 2½-day event, presentations covered a wide range of topics, from laboratory science to clinical trials. The workshop provided an opportunity for experts in the field to share their latest findings, collaborate on innovative approaches, and discuss challenges facing gene therapy for hemophilia. Overall, the workshop emphasized the need for continued research, development, and innovation to advance treatment options for those with hemophilia.

Click here or click on the player below to watch a video where Pierce summarizes and highlights some of the key themes that emerged from the meeting, including the latest findings on liver health, immunosuppression, and insertional mutagenesis.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.